New pill could let Sun-Sensitive patients enjoy the outdoors

NCT ID NCT06910358

Ongoing Disease control Sponsor: Disc Medicine, Inc Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 3 trial tests whether bitopertin, a daily pill, can help people with erythropoietic protoporphyria (EPP) or X-linked protoporphyria (XLP) spend more time in sunlight without pain. About 183 participants aged 12 and older will take bitopertin or a placebo for 6 months. The study measures pain-free sun exposure and changes in blood porphyrin levels.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Bitopertin

What this could lead to

If it works, this could provide a daily pill that allows people with EPP or XLP to spend more time in sunlight without pain.

What could go wrong

This is a Phase 3 trial, but results are not yet known. The drug may not work better than placebo, and side effects are possible.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

erythropoietic protoporphyria porphyria X-linked erythropoietic protoporphyria

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ERYTHROPOIETIC PROTOPORPHYRIA (EPP) X-LINKED PROTOPORPHYRIA (XLP)

Contacts and locations

Show contact details

Locations

CHU de Nantes - Hôtel Dieu, Service de dermatologie

Nantes, France, 44093, France
Centre d'Investigation Clinique (CIC) Hôpital Bichat - Claude-Bernard

Paris, France, 75018, France
Charité - Universitätsmedizin Berlin, Institute of Allergology

Berlin, Germany, 12203, Germany
Children's Health Ireland (CHI)

Dublin, D12N512, Ireland
Clinical Research Centre, Ninewells Hospital & Medical School , NHS Tayside

Dundee, Scotland, DD1 9SY, United Kingdom
Erasmus MC

Rotterdam, The Netherlands, 3015 GD, Netherlands
Guy's and St Thomas' NHS Foundation Trust

London, England, SE1 9RT, United Kingdom
Henry Ford Health System

Detroit, Michigan, 48202, United States
Hospital Clinic de Barcelona

Barcelona, Spain, 08036, Spain
Instituto Dermatologico San Gallicano Istituti Fisioterapici Ospitalieri IRCCS

Roma, 53-00144, Italy
Karolinska University Hospital

Stockholm, Sweden, 141 86, Sweden
Klinikum Chemnitz gGmbH

Chemnitz, Saxony, 09116, Germany
Marvel Clinical Research

Huntington Beach, California, 92647, United States
Massachusetts General Hospital

Boston, Massachusetts, 02115, United States
MetroBoston Clinical Partners

Boston, Massachusetts, 02135, United States
Mount Sinai Hospital

New York, New York, 10029, United States
Photobiology Unit, Salford Royal Hospital

Salford, M6 8HD, United Kingdom
Remington-Davis Clinical Research

Columbus, Ohio, 43215, United States
Royal Prince Alfred Hospital

Camperdown, New South Wales, 2050, Australia
The Royal Melbourne Hospital

Parkville, Victoria, 3050, Australia
UZ Leuven

Leuven, 3000, Belgium
University of Alberta

Edmonton, Alberta, T6G 2R3, Canada
University of California San Francisco

San Francisco, California, 94143, United States
University of Miami Miller School of Medicine

Miami, Florida, 33146, United States
University of Texas Medical Branch

Galveston, Texas, 77550, United States
University of Washington

Seattle, Washington, 98195, United States
Wake Forest University

Winston-Salem, North Carolina, 27157, United States